Healthcare / BiotechnologySwiss
$4.39
-0.08 (-1.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-388.2M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
9.8%
↑Gross Margin
90.5%
↑Debt/Equity
-1.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+31.5%
FCF CAGR
—
FCF margin
-75.7%
FCF / Net income
1.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $220.6M · net income $-111.7M · FCF $-167.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $220.6M | $220.6M | $112.5M | $152.4M | $97.1M |
| Net Income | $-111.7M | $-111.7M | $-263.8M | $-297.9M | $-827.9M |
| EBITDA | $-45.5M | $-45.5M | $-226.5M | $-254.6M | $-783.1M |
| EPS | -0.52 | -0.52 | -1.45 | -1.67 | -4.67 |
| Gross Margin | 90.5% | 90.5% | 68.1% | 95.3% | 93.5% |
| Operating Margin | -52.8% | -52.8% | -299.8% | -356.4% | -826.9% |
| Net Margin | -50.6% | -50.6% | -234.4% | -195.5% | -852.6% |
| Balance Sheet | |||||
| Debt/Equity | -1.11 | -1.11 | -1.04 | -1.24 | -1.86 |
| Current Ratio | 1.39 | 1.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-167.0M | $-167.0M | $-388.2M | $-638.7M | $-886.2M |
| Returns | |||||
| ROE | 9.8% | 9.8% | 21.8% | 30.8% | 125.3% |
| Growth & Yield | |||||
| Revenue Growth | 96.1% | 96.1% | -26.2% | 56.9% | — |
| EPS Growth | 64.1% | 64.1% | 13.2% | 64.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+180.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.45 → -0.52
Residual
+180.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.